Compare PTON & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTON | APLS |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.7B |
| IPO Year | 2019 | 2017 |
| Metric | PTON | APLS |
|---|---|---|
| Price | $6.40 | $23.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 19 |
| Target Price | $9.68 | ★ $33.11 |
| AVG Volume (30 Days) | ★ 10.2M | 2.4M |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $2,455,600,000.00 | $1,016,397,000.00 |
| Revenue This Year | $1.53 | $29.00 |
| Revenue Next Year | $1.42 | N/A |
| P/E Ratio | ★ N/A | $65.98 |
| Revenue Growth | N/A | ★ 42.11 |
| 52 Week Low | $4.63 | $16.10 |
| 52 Week High | $10.90 | $35.72 |
| Indicator | PTON | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 62.06 |
| Support Level | $6.37 | $20.51 |
| Resistance Level | $6.80 | $21.72 |
| Average True Range (ATR) | 0.32 | 0.81 |
| MACD | -0.02 | 0.51 |
| Stochastic Oscillator | 9.29 | 92.66 |
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product derives revenue from the portfolio of Connected Fitness Products and related accessories, as well as Precor-branded fitness products, delivery and installation services, Peloton Bike portfolio rental products, extended warranty agreements, branded apparel, and commercial service contracts. Subscription revenue is derived from monthly Subscription fees. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from International markets.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.